Author supplied keywords
- Add-on
- Adrenic acid (22:4 n -6)
- Alpha-linolenic acid (ALA, 18:3 n -3)
- Antipsychotic agent
- Apoptosis
- Arachidonic acid (AA-20:4 n -6)
- Arrythmia
- At-risk mental state
- Attention deficit hyperactivity disorder (ADHD)
- Attenuated psychotic symptoms
- Bipolar disorder
- Birthweight
- Bleeding time
- Body mass index (BMI)
- Brain development
- Brain tissue
- Brain water proton transverse relaxation times (T2)
- Breastfeeding
- Brief limited intermittent psychotic symptoms (BLIPS)
- Ca2+-independent PLA2 (iPLA2)
- Cardiovascular disease
- Cell signalling
- Cholesterol
- Chronic schizophrenia
- Cingulate cortex
- Clinical staging
- Cognitive behavioral therapy (CBT)
- Cytosolic Ca2+ -dependent PLA2 (cPLA2)
- Desaturases
- Diacyl glycerophospholipids (GPL)
- Diet
- Dihomogamma-linoleic acid (DGLA-20:3 n -6)
- Docosahexaenoic acid (DHA, 22:5 n -3)
- Dopaminergic activity
- Dyskinesia
- ELOVL2
- Eicosanoids
- Eicosapentaenoic acid (EPA, 20:5 n -3)
- Electroencephalography (EEG)
- Elongases
- Emerging psychosis
- Epidemiology
- Epistaxis
- Erythrocyte
- Essential fatty acids (EFA)
- Excitotoxicity
- Extrapyramindal side effects (EPS)
- FADS
- Fatty acid composition
- Fatty acids
- Fetal brain
- Fibroblast
- First episode psychosis
- Fish
- Frontal cortex
- Gestation
- Glutamate/glutamine (GLX)
- Glutathione (GSH)
- Haloperidol
- High-density lipoproteins (HDL)
- IQ
- Indicated prevention
- Inflammatory mediator
- Intracellular phospholipases A2 (in PLA2)
- Linoleic acid (LA, 18:2 n -6)
- Lipid metabolism
- Lipid peroxidation
- Long-chain PUFA (LC-PUFA)
- Low-density lipoproteins (LDL)
- Lysophospholipids
- Magnetic resonance imaging (MRI)
- Major depression
- Membrane-phospholipid hypothesis
- Metabolic syndrome
- Monoaminergic transmission
- Monotherapy
- Myelination
- Myelogenesis
- N -Acetylaspartate (NAA)
- Nervonic acid (24:1 n -9)
- Neurodevelopment
- Neuronal integrity
- Neuroprotection
- Niacin skin stimulation
- Nitric oxide (NO)
- Number needed to treat (NNT)
- Olanzapine
- Oleic acid (18:1 n -9)
- Omega-3 fatty acid-n -3 Fatty acid
- Omega-6 fatty acid
- Omega-9 fatty acid-n -6 PUFA-n -3 PUFA
- Orbitofrontal cortex
- Oxidative stress
- PLA2 GIIa
- PLA2 GIVa and PLA2 GVIa
- PLA2 isoenzymes
- Phosphatidylethanolamine (PE)
- Phosphatidylserine (PS)
- Phospholipase
- Phospholipases A2 (PLA2)
- Phospholipases C (PLC)
- Phospholipid structure
- Phospholipids
- Plasmalogens
- Platelet
- Polyunsaturated fatty acids (PUFA)
- Postmortem
- Postpartum
- Pregnancy
- Prostaglandin
- Prostaglandin-deficiency hypothesis
- Proton magnetic resonance spectroscopy (1H-MRS)
- Psychosis
- Psychotic disorder
- Red cell membrane
- Rheumatoid arthritis
- Risperidone
- Saturated fat
- Schizoaffective disorder
- Schizophrenia
- Seafood
- Secretory (extracellular) Ca2+ -dependent PLA2 (sPLA2)
- Sexual dysfunction
- Spectral analysis
- Sphingolipids
- Sugar
- Synaptic plasticity
- Tardive dyskinesia (TD)
- Thrombocyte
- Tolerability
- Triglyceride (TG)
- Ultrahigh risk (UHR)
- n-6 Fatty acid
Cite
CITATION STYLE
APA
Mossaheb, N., Schloegelhofer, M., Schaefer, M. R., Fusar-Poli, P., Smesny, S., McGorry, P., … Amminger, G. P. (2013). Long-chain omega-3 fatty acids and psychotic disorders. In Omega-6/3 Fatty Acids: Functions, Sustainability Strategies and Perspectives (pp. 149–178). Humana Press Inc. https://doi.org/10.1007/978-1-62703-215-5_9
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free